<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">Ischemic heart disease</z:e> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> in patients with SLE--are usually secondary to early <z:hpo ids='HP_0004929'>coronary atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Estimation if <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> are the risk factor for <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> in patients with TRU </plain></SENT>
<SENT sid="2" pm="."><plain>We examined 129 patients with SLE (114 women and 15 men) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients underwent comprehensive physical examination </plain></SENT>
<SENT sid="4" pm="."><plain>ECG, ultrasound heart examinations were performed </plain></SENT>
<SENT sid="5" pm="."><plain>They were followed by heart scintygraphic examination if indicated </plain></SENT>
<SENT sid="6" pm="."><plain>Routine biochemical and hematological laboratory tests were performed including fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> level, concentration of <z:chebi fb="0" ids="17230">homocysteine</z:chebi>, <z:chebi fb="3" ids="27226">uric acid</z:chebi> and <z:chebi fb="23" ids="18059">lipids</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Wide range of immunological essays were performed, testing for <z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo> (ANA), extractable nuclear antigen antibodies (ENA), <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (anticardiolipin antibodies--aCL, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>--LA, antiprothrombine antibodies aPT, anti-beta2glicoprotein-I antibodies), anti-dsDNA antibodies, anti-nucleosome antibodies, antihistone antibodies, antineutrophil cytoplasmic antibodies (<z:chebi fb="0" ids="34507">ANCA</z:chebi>) and antiendothelial antibodies (AECA) </plain></SENT>
<SENT sid="8" pm="."><plain>Statistical analysis was performed with chi2 Yates, chi2 Pearson and R rang Spearman tests </plain></SENT>
<SENT sid="9" pm="."><plain>Multivariate regression analysis was also done </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">Ischemic heart disease</z:e> was found in 20 (15.5%) SLE patients, <z:hpo ids='HP_0001658'>myocardial infarctions</z:hpo> were diagnosed in 9 (6.97%) </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">Ischemic heart disease</z:e> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> were significantly related to presence of <z:e sem="disease" ids="C0409983" disease_type="Disease or Syndrome" abbrv="">secondary antiphospholipid syndrome</z:e> (SAPS), OR: 4.21, p = 0.008 and OR: 12.8; p = 0.02 respectively) </plain></SENT>
<SENT sid="12" pm="."><plain>They were also related to high activity of SLE, OR: 7.18; p = 0.012 and OR: 27.3; p = 0.006 respectively </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">Ischemic heart disease</z:e> was significantly more common in older patients (52.75 years versus 42.15 years; p = 0.0008) and in patients with <z:hpo ids='HP_0000822'>hypertension</z:hpo> (p &lt; 0.05) </plain></SENT>
<SENT sid="14" pm="."><plain><z:hpo ids='HP_0000833'>Impaired glucose tolerance</z:hpo> (OR: 8.44; p = 0.03), presence of aCL IgG (OR; 2.93; p = 0.05) and p-<z:chebi fb="0" ids="34507">ANCA</z:chebi> anti-MPO (OR: 6.08; p = 0.036) were found to be risk factors of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain><z:hpo ids='HP_0001658'>Myocardial infarction</z:hpo> was significantly associated with high <z:chebi fb="3" ids="27226">uric acid</z:chebi> level (OR: 5.01; p = 0.052) and <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (OR: 7.42; p = 0.047) and with presence of the following antibodies: aCL IgG and/or aCL IgM (OR: 5.61; p = 0.039), <z:chebi fb="0" ids="34507">ANCA</z:chebi> in the indirect immunofluorescence essay (OR: 5.78; p = 0.035), anti-MPO antibodies (OR: 6.58; p = 0.051) and AECA (OR: 11.10; p = 0.026) </plain></SENT>
<SENT sid="16" pm="."><plain>Presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and SAPS are significant risk factors of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> in SLE patients </plain></SENT>
<SENT sid="17" pm="."><plain>The risk factors of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> in SLE patients significantly differ from the ones in general population </plain></SENT>
</text></document>